Clinical Trial Update: A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on UCART019 for relapsed/refractory CD19+ leukemia and lymphoma (Phase 1/2) conducted by Chinese PLA General Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• UCART019

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: B Cell Leukemia, B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN